Biocon demerges drug substance business
  • WebDesk BTVI
  • Apr 03 2019

Arun Chandavarkar, CEO and joint MD of Biocon, discusses about the rationale behind transferring drug substance business to the Biologics Unit for Rs 33.3 crore. He also says the organisation is looking at different options on how best to unlock the value.